CoreWeave Rally Hits Wall As Goldman Says “Execution Bar Was Quite High”
Shares of CoreWeave fell in premarket trading on Wednesday after the provider of artificial intelligence infrastructure reported solid revenue growth and backlog, but missed on capital expenditures and issued guidance that fell short of Wall Street’s most bullish expectations.
Investor focus this morning appears to be centered around CoreWeave’s 2Q operating margin, which contracted sharply from 20% to 2% year-over-year, primarily reflecting $145 million in stock-based compensation, while total debt increased to $11.1 billion.
CoreWeave reported 2Q revenue of $1.21 billion, more than tripling from $395.4 million a year ago, while narrowing its net loss to $290.5 million from $323 million versus the same quarter last year.
CoreWeave 2Q25 Earnings Summary
-
Shares fell 9% in premarket trading as quarterly net loss widened 20x to $130.8M, driven by margin pressure from rapid AI datacenter expansion.
-
Earnings Miss: EPS -.60 vs. -.21 expected.
-
Revenue Beat: $1.21B vs. $1.08B expected.
-
Profitability: Adj. EBITDA $753.2M vs. $249.8M a year ago.
-
Backlog: $30.1B.
Bloomberg Intelligence’s first take on CoreWeave, which by the way is a next-generation cloud infrastructure provider specializing in high-performance computing workloads rather than the broad, general-purpose services offered by traditional hyperscalers like AWS, Microsoft Azure, or Google Cloud, noted lower-than-expected CapEx and an above-consensus adjusted operating margin for the quarter. Analysts see this as a likely move to address the $30 billion backlog, which jumped roughly $4 billion sequentially.
Analysts had anticipated a stronger outlook, especially given the stock’s sharp rally since its March debut:
Guidance Q3
Revenue: $1.26B to $1.30B (in line with $1.25B expected).
Adj. Operating Income: $160M to $190M. Margins temporarily pressured by capacity ramp-up. Q3 CapEx: $2.9B to $3.4B. Q3 Interest Expense: $350M to $390M. Stock-Based Comp: Slightly elevated through 2025.
Full-Year 2025 Outlook
Revenue: Raised to $5.15B to $5.35B (vs. $5.04B expected).
Adj. Operating Income: Unchanged at $800M to $830M.
CapEx: $20B to $23B.
“We are scaling rapidly as we look to meet the unprecedented demand for AI,” CEO Michael Intrator wrote in a statement.
Here is Goldman analyst Kash Rangan’s first take on the earnings, which pointed out “the bar for execution was quite high“, hence the stock selling off in premarket trading. He maintained a “Neutral” rating on the stock with a 12-month $120 price target.
Pro subs can find Rangan’s full note in the usual place.
Tyler Durden Wed, 08/13/2025 – 08:45
Source: https://freedombunker.com/2025/08/13/coreweave-rally-hits-wall-as-goldman-says-execution-bar-was-quite-high/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
